No active federal class action exists against Great HealthWorks over Omega XL. This is confirmed as of July 2026. The verified legal record has three parts. First, an FDA warning letter dated June 23, 2021. It cited both OmegaXL and ProbioticXL for unapproved drug claims. ProbioticXL also got cited for misbranded health claims.

Second, a 2015 NAD decision. NAD found some OmegaXL claims supportable. It recommended dropping others, like “breakthrough secret” and “no known drug interactions.” Third, a 2017 case: Boyer et al v. Great HealthWorks, Inc. Filed in the Southern District of California, No. 17-cv-734. It alleged deceptive subscription enrollment.

Consumer complaints about auto-ship billing continue through the Better Business Bureau into 2026. Claims of an active 2025–2026 class certification proceeding could not be verified. No matching court docket exists.

Is there an active Omega XL lawsuit in 2026? No. Public court records show no confirmed active class action as of this update. The verified history includes the 2021 FDA warning letter, the 2015 NAD decision, and the 2017 subscription-billing case. Recent BBB complaints show ongoing billing disputes. But complaints aren’t a lawsuit.

Key Takeaways

• The FDA warning letter (June 23, 2021) cited two products, not just OmegaXL; ProbioticXL was flagged for both unapproved drug claims and unauthorized health claims.
• NAD’s 2015 review found mixed results: some OmegaXL research claims were considered supportable evidence; others, like “breakthrough secret,” were recommended for removal.
• The verified 2017 lawsuit (Boyer v. Great HealthWorks) addressed subscription billing, not product safety or efficacy.
• No verifiable record confirms an active 2025–2026 class certification case, despite claims on some websites.
• Auto-ship billing complaints remain the most current, verifiable consumer issue, documented directly through BBB complaint records into 2026.
• Great HealthWorks continues to operate and sell Omega XL and remains subject to standard FDA oversight.

What Is Omega XL and Who Makes It

Omega XL is a dietary supplement manufactured and sold by Great HealthWorks, Inc., a direct-response marketing company based in Fort Lauderdale, Florida. The product’s key ingredient is PCSO-524, a proprietary lipid extract derived from the New Zealand green-lipped mussel, which the company markets as a joint health and anti-inflammatory supplement. Great HealthWorks also sells ProbioticXL, a separate gut-health supplement that appears alongside OmegaXL in the FDA’s 2021 enforcement action.

Both products are sold primarily direct-to-consumer through infomercials, celebrity endorsements, and a subscription-based auto-ship model. A distribution structure that recurs throughout this product’s legal and regulatory history, particularly in consumer billing complaints.

As a dietary supplement rather than an FDA-approved drug, Omega XL falls under the Dietary Supplement Health and Education Act (DSHEA). Manufacturers don’t need pre-market FDA approval, but they can’t market a supplement using language that implies it treats, cures, or prevents disease. A distinction central to the 2021 FDA warning letter below.

Is There an Active Omega XL Class Action Lawsuit?

No confirmed active class action exists in public court records as of July 2026. Several websites describe an “active” or “significant phase” class action moving toward class certification in 2025–2026. None of these claims include a case name, docket number, or court citation that could be independently verified. Treat these claims with caution; see the fact-check section for a direct comparison.

What is verifiable:

Matter	Type	Date	Status	Subject
FDA Warning Letter (MARCS-CMS 611686)	Regulatory enforcement	June 23, 2021	Closed enforcement letter	Unapproved drug claims, misbranded health claims
NAD Advertising Review	Industry self-regulation	August 6, 2015	Decision published; not legally binding	Substantiation of clinical and safety claims
Boyer et al v. Great HealthWorks, Inc. (No. 17-cv-734, S.D. Cal.)	Federal civil case	Filed March 2017, transferred to federal court April 2017	Historical; current docket status not independently confirmed in this update	Deceptive subscription enrollment
BBB Complaints	Consumer complaints	Ongoing through 2026	Active, non-litigation	Auto-ship billing, refund disputes

 

The FDA Warning Letter, Explained Clause by Clause

The FDA reviewed Great HealthWorks’ website in May 2021 and issued a warning letter on June 23, 2021 (21-HAFE4-WL-06, MARCS-CMS 611686), addressed to CEO Ken Meares. The letter cited violations for both OmegaXL and ProbioticXL, a detail most secondary coverage omits.

1. Unapproved New Drug Claims (Both Products)

The FDA determined that marketing language on Great HealthWorks’ websites made both products drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act, because the claims were intended to cure, mitigate, treat, or prevent disease. Cited examples included:

For OmegaXL:

• “Shown to help relieve joint pain due to inflammation”
• “OmegaXL is widely recognized as a leader in natural relief from pain due to inflammation”
• A claim citing an “89% improvement in joint discomfort due to inflammation” from a 50-participant study
• “Demonstrated in over 30 years of clinical research to help relieve joint discomfort due to inflammation”

For ProbioticXL:

• “Combats bad bacteria”
• “Reduce abdominal pain”
• “Reduce the risk factors of cardiovascular disease, especially in smokers”
• “Alleviate inflammation in the large intestine”
• Multiple ingredient-specific disease claims tied to individual bacterial strains

2. Misbranded Food (ProbioticXL Only)

Separately, the FDA found ProbioticXL’s labeling carried unauthorized health claims under section 403(r)(1)(B), specifically, claims that its ingredients “reduce the risk factors of cardiovascular disease.” These claims weren’t authorized by FDA regulation or the health claim notification process, making the product misbranded regardless of the drug-claim issue above.

Important clarification: This misbranding finding applied to ProbioticXL’s health claims, not to OmegaXL’s label formatting or serving size. A distinction blurred in some online summaries that describe both products as “misbranded” without specifying which violation applied to which product.

Great HealthWorks was given 15 working days to respond with corrective steps. Public FDA records don’t show further escalation, product seizure, or injunction after this letter.

The 2015 NAD Advertising Decision

Before the FDA letter, Omega XL’s marketing claims were independently reviewed by the National Advertising Division (NAD), an investigative unit of BBB National Programs that administers industry self-regulation. On August 6, 2015, following a challenge from the Council for Responsible Nutrition, NAD published a decision with mixed findings, a nuance that’s often flattened into a simple “NAD found the claims false” narrative online.

What NAD found supportable: NAD reviewed eight clinical studies on the Omega XL preparation conducted over roughly 30 years, including one randomized, placebo-controlled trial involving 80 subjects over six months that used a validated pain assessment scale. NAD considered this trial competent and reliable evidence for certain pain-relief claims.

What NAD recommended discontinuing or modifying:

• “Omega XL is so potent it requires only a very small dose to be effective”
• “No known drug interactions” and “does not interfere with other medications”
• Claims of having none of the “common side effects” associated with standard fish, krill, or salmon oils
• The characterization of Omega XL as a “breakthrough secret,” since a product studied for roughly 30 years doesn’t meet the definition of new or breakthrough
• Unqualified claims of containing “no levels of harmful toxins or PCBs,” which NAD said should be phrased as “none detected” rather than a guarantee

Note on NAD’s authority: NAD is a self-regulatory body, not a government agency or court. Its recommendations aren’t legally binding; advertisers can, and sometimes do, disagree with findings while still adjusting their marketing. Great HealthWorks’ official response stated it would take NAD’s recommendations “into account” while disagreeing with some of them.

Boyer v. Great HealthWorks: The Subscription Billing Case

In March 2017, a class action was filed in state court against Great HealthWorks, later transferred to the U.S. District Court for the Southern District of California in April 2017 as Boyer et al v. Great HealthWorks, Inc. and Does 1-50 (Case No. 17-cv-734). The named plaintiff alleged she wasn’t adequately informed that her initial Omega XL purchase would automatically enroll her in a recurring monthly subscription, resulting in unexpected charges.

This case addressed negative-option billing practices, not product safety or efficacy claims. Some secondary sources report the case was voluntarily dismissed in March 2018; this detail appears in single-source reporting and couldn’t be independently confirmed against a primary docket in this update. Readers relying on this case for current legal status should verify directly through PACER.

Current Consumer Complaints: What BBB Records Show

Separate from any historical litigation, the Better Business Bureau’s complaint records for Great HealthWorks show an active, ongoing pattern of billing disputes into 2026. Complaints reviewed for this article, dated as recently as 2026, describe:

• Customers are being charged for auto-ship shipments after requesting cancellation
• Difficulty reaching customer service to stop recurring orders
• Refund requests that customers say went unresolved for months

Great HealthWorks has responded to individual complaints on the BBB platform, in some cases confirming subscription cancellations and describing its auto-ship terms as disclosed at signup. These are unresolved consumer disputes on record with a third-party complaint platform, not court filings, and not evidence of a pending lawsuit. They’re worth noting because they represent the most current, verifiable evidence of ongoing customer friction, distinct from the older regulatory and legal history above.

Fact-Check: Claims We Could Not Verify

Claim seen online	Verifiable?	What the record actually shows
“FDA warning letter issued June 31, 2021”	Not accurate	June has 30 days. The letter is dated June 23, 2021, per FDA.gov.
“NAD took action against Great HealthWorks in 2026”	Not accurate	The NAD decision was published on August 6, 2015.
“Active class action moving toward class certification in 2025–2026”	Not verifiable	No case name, docket number, or court citation located for a current product-liability or false-advertising class action.
“FDA warning letter cited OmegaXL’s label formatting/serving size as misbranded”	Not accurate	The misbranding finding applied specifically to ProbioticXL’s unauthorized health claims, not to OmegaXL’s label formatting.
“2023 ADA website accessibility lawsuit”	Single unverified source	Referenced on one website without a locatable case citation. Treat as unconfirmed.

This isn’t a complete list of every claim circulating about Omega XL. It reflects what couldn’t be confirmed against primary sources at the time of writing. Readers should verify any current litigation claims directly through federal court records (PACER) rather than aggregator sites.

Complete Timeline

• March 2017: Boyer et al v. Great HealthWorks, Inc. was filed in California state court, alleging deceptive subscription enrollment.
• April 2017: Case transferred to the U.S. District Court for the Southern District of California.
• August 6, 2015 (predates the above chronologically but is grouped here for completeness of the regulatory record): NAD publishes its decision on Omega XL advertising claims following a Council for Responsible Nutrition challenge.
• May 2021: FDA reviews Great HealthWorks’ website and marketing materials.
• June 23, 2021: FDA issues warning letter MARCS-CMS 611686 covering OmegaXL and ProbioticXL.
• 2021–2026: No further public FDA enforcement escalation located in agency databases.
• 2025–2026: BBB complaint records show ongoing auto-ship billing disputes; the company responds to individual complaints on the platform.

What This Means If You’re a Customer

If you’re currently using Omega XL or ProbioticXL

No verified record links either product to an active injury-based lawsuit. The FDA’s concern was with marketing language, not a product safety recall. If you experience an adverse reaction, report it through the FDA’s MedWatch program.

If you’re dealing with unwanted auto-ship charges

This is the most current, documented issue with Great HealthWorks. Cancel in writing, keep records of your cancellation request and any confirmation, and file a BBB complaint if the company doesn’t honor it. This creates a documented paper trail.

If you’re evaluating the product’s health claims

NAD’s 2015 review found genuine clinical research behind some pain-relief claims, while flagging others as unsupported. Treat “clinically proven” marketing language with the nuance NAD applied; some claims have real backing, others don’t, and it’s not an all-or-nothing situation.

If you’re citing this topic in your own research

Use the FDA warning letter, the NAD decision summary (published by BBB National Programs), and TINA.org’s case tracking as primary sources rather than aggregator articles that don’t distinguish between regulatory action, self-regulatory review, closed litigation, and unverified claims.

FAQs

Is there an active Omega XL lawsuit in 2026?

No class action against Great HealthWorks over Omega XL could be verified as active in public court records as of this update. Ongoing BBB billing complaints exist but are not in litigation.

Did the FDA ban or recall Omega XL?

No. The FDA issued a warning letter in 2021 addressing marketing language, not a product ban or recall.

Did the FDA warning letter only cover Omega XL?

No. It covered both OmegaXL and ProbioticXL. ProbioticXL was cited for both unapproved drug claims and unauthorized health claims on its labeling.

What did the National Advertising Division find about Omega XL?

A mixed result. NAD found some clinical research claims supportable, including a placebo-controlled study on 80 subjects, but recommended discontinuing several other claims, including “breakthrough secret” and “no known drug interactions.”

What was the 2017 lawsuit about?

Boyer v. Great HealthWorks alleged deceptive enrollment in a recurring subscription program.  A billing dispute, not a product safety or efficacy claim.

Is Great HealthWorks still selling Omega XL?

Yes. The company continues to operate and sell Omega XL and ProbioticXL through its subscription-based direct-to-consumer model.

What should I do if I’m having trouble canceling my subscription?

Request cancellation in writing, save all correspondence, and file a complaint with the Better Business Bureau if the issue isn’t resolved. This creates a documented record if further action becomes necessary.

Sources

• U.S. Food and Drug Administration, Great Healthworks, Inc. Warning Letter, MARCS-CMS 611686, June 23, 2021
• BBB National Programs, NAD Recommends Great HealthWorks Modify, Discontinue Certain Claims for ‘Omega XL’, August 6, 2015
• Truth in Advertising (TINA.org), Subscriptions for Omega XL
• Better Business Bureau, Great HealthWorks, Inc. Complaint Records